TFEB Activation to Restore Lysosomal Biogenesis in Parkinson's Disease Dopaminergic Networks
🧪 Overview
Age-related decline in lysosomal function contributes to the accumulation of pathological protein aggregates in Parkinson's disease, particularly alpha-synuclein oligomers and Lewy bodies that disrupt dopaminergic neurotransmission and cause progressive motor dysfunction. This hypothesis proposes that pharmacological or genetic activation of TFEB (Transcription Factor EB) can restore lysosomal biogenesis and autophagy flux specifically in dopaminergic neurons of the substantia nigra and striatal terminals. TFEB, a master regulator of the autophagy-lysosomal pathway, becomes sequestered in the cytoplasm during neurodegeneration, reducing its nuclear translocation and transcriptional activity in vulnerable dopaminergic populations. By enhancing TFEB nuclear localization through mTORC1 inhibition, trehalose treatment, or direct TFEB overexpression, we can upregulate expression of lysosomal genes including LAMP1, cathepsins, and V-ATPase subunits specifically in dopaminergic circuits.
...🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["mTORC1 Hyperactivation<br/>Nutrient/Growth Signals"]
B["TFEB Phosphorylation<br/>Ser211 by mTORC1"]
C["14-3-3 Sequestration<br/>Cytoplasmic Retention"]
D["Lysosomal Biogenesis<br/>Blocked"]
E["Autophagic Flux<br/>Impaired"]
F["Tau/Amyloid Aggregate<br/>Accumulation"]
G["TFEB Activation<br/>Rapamycin or MCOLN1"]
H["Nuclear TFEB<br/>CLEAR Gene Expression"]
G --> H
H -.->|"rescues"| D
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TFEB
No curated PDB or AlphaFold mapping for TFEB yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TFEB from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TFEB.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF early-stage Parkinson's disease patients (Hoehn-Yahr ≤2, disease duration <3 years) receive TFEB activator treatment for 18 months, THEN cerebrospinal fluid GCase activity will increase by ≥30% fro | CSF GCase activity ratio (post-treatment/baseline) ≥1.30, with simultaneous reduction in CSF alpha-synuclein oligomers by ≥20% | — no observation — | pending | 0.55 |
| IF 6-month-old MPTP-intoxicated C57BL/6J mice receive daily trehalose (2% in drinking water) for 12 weeks, THEN striatal dopamine levels will increase by at least 25% compared to vehicle-treated MPTP | Striatal dopamine concentration ≥1.8 μg/mg tissue (vs. expected ~1.4 μg/mg in vehicle controls) | — no observation — | pending | 0.65 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |